sch 23982 has been researched along with Meningioma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fahlbusch, R; Nomikos, P; Schrell, UM | 1 |
| Adams, EF; Fahlbusch, R; Nomikos, P; Reif, M; Schrell, UM | 1 |
2 other study(ies) available for sch 23982 and Meningioma
| Article | Year |
|---|---|
Presence of dopamine D1 receptors and absence of dopamine D2 receptors in human cerebral meningioma tissue.
Topics: Adult; Aged; Benzazepines; Female; Guanylyl Imidodiphosphate; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1992 |
Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents. Presence of high affinity dopamine-D1 receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Apomorphine; Benzazepines; Binding, Competitive; Bromocriptine; Butaclamol; Cell Division; Dopamine; Dopamine Agents; Humans; Meningioma; Receptors, Dopamine; Receptors, Dopamine D1; Tumor Cells, Cultured | 1990 |